<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917680</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-angiodema</org_study_id>
    <nct_id>NCT03917680</nct_id>
  </id_info>
  <brief_title>Evaluation of New Markers in Type 3 Angioedema</brief_title>
  <official_title>Evaluation of New Markers (FXII and Videocapillaroscopy) in Type 3 Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angioedema is a common condition, with multiple etiologies.

      Type 3 angioedema is caused by an increase in kininogenase activity responsible for an
      increased production of bradykinin. In some cases, it may be associated with clotting factor
      12 mutations. However, other genetic abnormalities remain to be identified.

      Clinically, this angioedema type 3 is similar to types 1 and 2. The patient's vital prognosis
      is good if the diagnosis is made and if they have access to the appropriate treatment.
      Otherwise a significant morbidity is associated with it, hence the importance of being able
      to define a diagnostic marker.

      Videocapillaroscopy might be able to highlight abnormalities in the microcirculation of
      patients with a clinical display of angioedema.

      The purpose of this study is to highlight markers allowing to make an early diagnosis of
      angioedema. Functional analysis of factor XII in patients with symptoms of angioedema may be
      an interesting marker for diagnosis.

      Microcirculation abnormalities will also be evaluated by videocapillaroscopy, which may be
      another indicator of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">October 8, 2019</completion_date>
  <primary_completion_date type="Actual">October 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Factor XII</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma concentration of Factor XII</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of p.Thr328Lys mutation</measure>
    <time_frame>24 hours</time_frame>
    <description>Genetic analysis : sequencing of the Factor VII gene. Presence/Absence of the p.Thr328Lys mutation (single nucleotide variation inducing a missense variant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Videocapillaroscopy result</measure>
    <time_frame>24 hours</time_frame>
    <description>It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.The result will be classified as 'normal' or 'abnormal' by the videocapillaroscopy specialist.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Angio Edema</condition>
  <arm_group>
    <arm_group_label>Type III angioedema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic angioedema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type I or II angioedema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post IEC (conversion enzyme inhibitors) angioedema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Histaminic angioedema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy individuals, no angioedema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Factor XII dosage</intervention_name>
    <description>Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.</description>
    <arm_group_label>Histaminic angioedema</arm_group_label>
    <arm_group_label>Idiopathic angioedema</arm_group_label>
    <arm_group_label>Post IEC (conversion enzyme inhibitors) angioedema</arm_group_label>
    <arm_group_label>Type I or II angioedema</arm_group_label>
    <arm_group_label>Type III angioedema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>p.Thr328Lys mutation detection</intervention_name>
    <description>Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.</description>
    <arm_group_label>Histaminic angioedema</arm_group_label>
    <arm_group_label>Idiopathic angioedema</arm_group_label>
    <arm_group_label>Post IEC (conversion enzyme inhibitors) angioedema</arm_group_label>
    <arm_group_label>Type I or II angioedema</arm_group_label>
    <arm_group_label>Type III angioedema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Videocapillaroscopy</intervention_name>
    <description>It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Histaminic angioedema</arm_group_label>
    <arm_group_label>Idiopathic angioedema</arm_group_label>
    <arm_group_label>Post IEC (conversion enzyme inhibitors) angioedema</arm_group_label>
    <arm_group_label>Type I or II angioedema</arm_group_label>
    <arm_group_label>Type III angioedema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Population of patients treated within the CHU Brugmann Hospital for an angioedema (and
             control group of healthy individuals)

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oumnia Mouna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Olivier Michel</investigator_full_name>
    <investigator_title>Head of immuno-allergology clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

